Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106 isolates) at <or=256 microg/ml and molds (including 10 Aspergillus isolates) at <or=1,024 microg/ml. All fungi were inhibited by omiganan at concentrations well below the 1% (10,000 microg/ml) clinical formulation, including species with reduced susceptibility to azoles and echinocandins.
Fritsche
Thomas R
TR
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. thomas-fritsche@jmilabs.com
Rhomberg
Paul R
PR
Sader
Helio S
HS
Jones
Ronald N
RN
D000935:Antifungal Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D001228:Aspergillosis / Q000382:microbiology; D001230:Aspergillus / Q000145:classification / Q000187:drug effects; D002175:Candida / Q000145:classification / Q000187:drug effects; D002177:Candidiasis / Q000382:microbiology; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D025141:Drug Resistance, Fungal; D016469:Fungemia / Q000382:microbiology*; D005658:Fungi / Q000145:classification* / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards
D000935:Antifungal Agents; D023181:Antimicrobial Cationic Peptides; C478918:omiganan pentahydrochloride